NAFLD vs MAFLD:南亚NAFLD患者不赞成改名

Shivaram P Singh, Prajna Anirvan, Amna S Butt, Ananta Shrestha, Anuradha S Dassanayake, Bashir A Shaikh, Mamun A Mahtab
{"title":"NAFLD vs MAFLD:南亚NAFLD患者不赞成改名","authors":"Shivaram P Singh,&nbsp;Prajna Anirvan,&nbsp;Amna S Butt,&nbsp;Ananta Shrestha,&nbsp;Anuradha S Dassanayake,&nbsp;Bashir A Shaikh,&nbsp;Mamun A Mahtab","doi":"10.5005/jp-journals-10018-1363","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>There have been vociferous attempts to change the name of Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Associated Fatty Liver Disease (MAFLD). Of the many arguments put forth in support of this, an important one is the presumed demand by patient groups insisting on the change. However, this claim does not have credible evidence to support it. Therefore, we decided to conduct a survey among South Asian NAFLD patients to understand their perspectives with regard to the change in nomenclature.</p><p><strong>Materials and methods: </strong>The study was conducted at multiple centers across South Asia from January 2021 to June 2021. Patients were surveyed using an 8-question survey questionnaire and responses were categorized by multiple-choice format.</p><p><strong>Results: </strong>Of 218 patients surveyed, 80.3% of the patients were not aware of the entity \"NAFLD\" before they were first diagnosed. Although 74.3% of patients admitted to being questioned about alcohol intake at the time of the first diagnosis, 75.9% of female patients were not questioned regarding this. After being labelled NAFLD, 92.1% of patients were never questioned again about alcohol intake. While 86.3% of patients found the term \"NAFLD\" consoling, 83% did not feel that \"Non\" in NAFLD trivialized their problem. In addition, only 6.9% of patients were scared of developing cardiovascular disease.</p><p><strong>Conclusion: </strong>The term \"NAFLD\" destigmatizes patients of the taboo associated with alcohol use. It was found to be consoling to most patients and they did not feel it trivialized their problem. A change of name without considering patients' perspectives and peculiarities specific to different populations will have enormous ramifications for both patients and physicians.</p><p><strong>Clinical significance: </strong>Our survey clearly shows that patients are happy with the term \"NAFLD\" and it effectively destigmatizes them from the taboo of alcohol. This would lead to higher compliance with management and greater patient participation in future studies and trials.</p><p><strong>How to cite this article: </strong>Singh SP, Anirvan P, Butt AS, <i>et al</i>. NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S1-S4.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 Suppl 1","pages":"S1-S4"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/2b/ejohg-12-s1.PMC9681577.pdf","citationCount":"1","resultStr":"{\"title\":\"NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.\",\"authors\":\"Shivaram P Singh,&nbsp;Prajna Anirvan,&nbsp;Amna S Butt,&nbsp;Ananta Shrestha,&nbsp;Anuradha S Dassanayake,&nbsp;Bashir A Shaikh,&nbsp;Mamun A Mahtab\",\"doi\":\"10.5005/jp-journals-10018-1363\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>There have been vociferous attempts to change the name of Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Associated Fatty Liver Disease (MAFLD). Of the many arguments put forth in support of this, an important one is the presumed demand by patient groups insisting on the change. However, this claim does not have credible evidence to support it. Therefore, we decided to conduct a survey among South Asian NAFLD patients to understand their perspectives with regard to the change in nomenclature.</p><p><strong>Materials and methods: </strong>The study was conducted at multiple centers across South Asia from January 2021 to June 2021. Patients were surveyed using an 8-question survey questionnaire and responses were categorized by multiple-choice format.</p><p><strong>Results: </strong>Of 218 patients surveyed, 80.3% of the patients were not aware of the entity \\\"NAFLD\\\" before they were first diagnosed. Although 74.3% of patients admitted to being questioned about alcohol intake at the time of the first diagnosis, 75.9% of female patients were not questioned regarding this. After being labelled NAFLD, 92.1% of patients were never questioned again about alcohol intake. While 86.3% of patients found the term \\\"NAFLD\\\" consoling, 83% did not feel that \\\"Non\\\" in NAFLD trivialized their problem. In addition, only 6.9% of patients were scared of developing cardiovascular disease.</p><p><strong>Conclusion: </strong>The term \\\"NAFLD\\\" destigmatizes patients of the taboo associated with alcohol use. It was found to be consoling to most patients and they did not feel it trivialized their problem. A change of name without considering patients' perspectives and peculiarities specific to different populations will have enormous ramifications for both patients and physicians.</p><p><strong>Clinical significance: </strong>Our survey clearly shows that patients are happy with the term \\\"NAFLD\\\" and it effectively destigmatizes them from the taboo of alcohol. This would lead to higher compliance with management and greater patient participation in future studies and trials.</p><p><strong>How to cite this article: </strong>Singh SP, Anirvan P, Butt AS, <i>et al</i>. NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S1-S4.</p>\",\"PeriodicalId\":11992,\"journal\":{\"name\":\"Euroasian Journal of Hepato-Gastroenterology\",\"volume\":\"12 Suppl 1\",\"pages\":\"S1-S4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/2b/ejohg-12-s1.PMC9681577.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euroasian Journal of Hepato-Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10018-1363\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euroasian Journal of Hepato-Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10018-1363","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

目的:有很多人试图将非酒精性脂肪性肝病(NAFLD)更名为代谢相关脂肪性肝病(MAFLD)。在支持这一观点的众多论据中,一个重要的论据是患者群体坚持改变的假定要求。然而,这种说法并没有可靠的证据来支持。因此,我们决定在南亚NAFLD患者中进行一项调查,以了解他们对命名法变化的看法。材料和方法:该研究于2021年1月至2021年6月在南亚的多个中心进行。采用8题调查问卷对患者进行调查,问卷的回答采用多项选择的形式进行分类。结果:218例被调查的患者中,80.3%的患者在首次诊断前不知道“NAFLD”这个实体。尽管74.3%的患者承认在第一次诊断时被问及酒精摄入量,但75.9%的女性患者没有被问及这一点。在被标记为NAFLD后,92.1%的患者不再被询问酒精摄入量。虽然86.3%的患者认为“NAFLD”一词令人宽慰,但83%的患者并不认为NAFLD中的“非”使他们的问题变得无足轻重。此外,只有6.9%的患者害怕患心血管疾病。结论:“NAFLD”一词使患者摆脱了与饮酒有关的禁忌。研究发现,这对大多数病人来说是一种安慰,他们并不觉得这轻视了他们的问题。在不考虑不同人群的患者观点和特点的情况下更改名称将对患者和医生产生巨大的影响。临床意义:我们的调查清楚地表明,患者对“NAFLD”这个词很满意,这有效地消除了他们对酒精禁忌的污名。这将导致更高的依从性管理和更多的患者参与未来的研究和试验。如何引用本文:Singh SP, Anirvan P, Butt AS等。NAFLD vs MAFLD:南亚NAFLD患者不赞成改名中华肝病与胃肠病杂志,2012;12(增刊1):S1-S4。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.

Aim: There have been vociferous attempts to change the name of Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Associated Fatty Liver Disease (MAFLD). Of the many arguments put forth in support of this, an important one is the presumed demand by patient groups insisting on the change. However, this claim does not have credible evidence to support it. Therefore, we decided to conduct a survey among South Asian NAFLD patients to understand their perspectives with regard to the change in nomenclature.

Materials and methods: The study was conducted at multiple centers across South Asia from January 2021 to June 2021. Patients were surveyed using an 8-question survey questionnaire and responses were categorized by multiple-choice format.

Results: Of 218 patients surveyed, 80.3% of the patients were not aware of the entity "NAFLD" before they were first diagnosed. Although 74.3% of patients admitted to being questioned about alcohol intake at the time of the first diagnosis, 75.9% of female patients were not questioned regarding this. After being labelled NAFLD, 92.1% of patients were never questioned again about alcohol intake. While 86.3% of patients found the term "NAFLD" consoling, 83% did not feel that "Non" in NAFLD trivialized their problem. In addition, only 6.9% of patients were scared of developing cardiovascular disease.

Conclusion: The term "NAFLD" destigmatizes patients of the taboo associated with alcohol use. It was found to be consoling to most patients and they did not feel it trivialized their problem. A change of name without considering patients' perspectives and peculiarities specific to different populations will have enormous ramifications for both patients and physicians.

Clinical significance: Our survey clearly shows that patients are happy with the term "NAFLD" and it effectively destigmatizes them from the taboo of alcohol. This would lead to higher compliance with management and greater patient participation in future studies and trials.

How to cite this article: Singh SP, Anirvan P, Butt AS, et al. NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S1-S4.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信